Eyestem announces a significant milestone against an incurable form of blindness which affects over 150 M people globally (About Dry AMD)
We are delighted to share positive animal efficacy results from Dr. Trevor McGill ( About Dr. Trevor McGill) at the Oregon Health and Science University for Eyecyte-RPE: our lead product for treatment of Dry AMD (macular degeneration)
- As per Dr.McGill "Eyecyte-RPE providedsignificant beneficial effects on the degenerating retina in RCS ratswithout any significant safety concerns suggesting this cell type may have significant therapeutic value in human retinal degenerative disease".
- Dr. Jogin Desai, Founder and CEO, Eyestem Research said " The POC results have shown significant preservation of photoreceptors and functional rescue of vision and the results are at par or better than most published data globally. We will be using this momentum to now aggressively move forward into GLP toxicology, larger efficacy and GMP production for our product for Dry AMD."